Basal Cell Carcinoma

Libtayo(Cemiplimab) approved in Canada for locally advanced basal cell carcinoma (BCC) patients

MISSISSAUGA, ON, Oct. 29, 2021  Libtayo® (cemiplimab) is now approved in Canada for the treatment of adults with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI).The approval of Libtayo follows the European Commission (EC) approval announced in June 2021 and the US in February 2021. With today's announcement, Libtayo is now offered as…